Enabling cures for
liver cancer

First-in-class liver EV tests

WHO ARE THE PATIENTS?

High-risk population for liver cancer

The high-risk population for liver cancer includes individuals with chronic viral hepatitis (B and C), non-alcoholic steatohepatitis (NASH), cirrhosis, excessive alcohol intake, exposure to aflatoxin, hereditary liver conditions, and those with a family history of liver cancer. Regular screening is vital for this group.

Mursla Bio is currently conducting a clinical study with hundreds of liver-cancer and high-risk patients to validate its novel IVD test.

Damaged liver transparent background tone down.jpg

WHAT DO WE ANALYSE?

Liver-derived EVs in blood

Extracellular Vesicles (EVs) have been shown to reflect the state of their cellular sources, transporting specific ‘-omics’ information (DNA, RNA, proteins, lipids and metabolites) either locally or to distant sites via the circulatory system, including blood.
Extracellular Vesicles from specific tissue, such as liver, are dynamic circulating snapshots of tissue activity and can be analysed non-invasively with a blood draw.

mursla_site_illustration_cell_exosome-01

LEARN MORE

HOW DO WE ANALYSE?

Novel EV characterisation platform ExoPheno

TM

ExoPheno™ analyses the multi-omics cargo of EVs in blood from a selected tissue of origin, such as liver. It enables the creation of next generation IVD tests.

It consists of proprietary and patented technologies, which integrate wet lab (validated EV tissue-of-origin markers, adaptative linker cleavage, pre-analytical multi-omics sequencing workflow and ultrasensitive EV marker detection systems) and dry lab analysis via machine learning.

LEARN MORE